ImmuCell Corp
NASDAQ:ICCC
ImmuCell Corp
Gross Profit
ImmuCell Corp
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ImmuCell Corp
NASDAQ:ICCC
|
Gross Profit
$3.9m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
2%
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is ImmuCell Corp's Gross Profit?
Gross Profit
3.9m
USD
Based on the financial report for Dec 31, 2023, ImmuCell Corp's Gross Profit amounts to 3.9m USD.
What is ImmuCell Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
2%
Over the last year, the Gross Profit growth was -49%. The average annual Gross Profit growth rates for ImmuCell Corp have been -17% over the past three years , -6% over the past five years , and 2% over the past ten years .